InsuletPODD
PODD
About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Employees: 3,000
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
27% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 71
13% more capital invested
Capital invested by funds: $14.3B [Q2] → $16.2B (+$1.89B) [Q3]
3% more funds holding
Funds holding: 588 [Q2] → 607 (+19) [Q3]
5% less repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 231
1.5% less ownership
Funds ownership: 101.44% [Q2] → 99.93% (-1.5%) [Q3]
29% less call options, than puts
Call options by funds: $163M | Put options by funds: $228M
75% less funds holding in top 10
Funds holding in top 10: 8 [Q2] → 2 (-6) [Q3]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$234
13%
downside
Avg. target
$274
3%
upside
High target
$317
18%
upside
9 analyst ratings
8 positive
89%
1 neutral
11%
0 negative
0%
Barclays Matt Miksic 0 / 0 met price target | 13%downside $234 | Equal-Weight Maintained | 11 Nov 2024 |
Morgan Stanley Patrick Wood 0 / 0 met price target | 18%upside $317 | Overweight Maintained | 11 Nov 2024 |
BTIG Marie Thibault 100% 1-year accuracy 5 / 5 met price target | 1%upside $270 | Buy Maintained | 8 Nov 2024 |
Bernstein Lee Hambright 0 / 0 met price target | 12%upside $300 | Outperform Initiated | 6 Nov 2024 |
Raymond James Jayson Bedford 75% 1-year accuracy 3 / 4 met price target | 3%downside $260 | Outperform Maintained | 14 Oct 2024 |
Financial journalist opinion
Based on 19 articles about PODD published over the past 30 days
Positive
Reuters
8 hours ago
Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case
Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.
Neutral
Business Wire
1 day ago
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (“EOFlow") in federal court. After a four-week trial in the U.S. District Court for the District of Massachusetts in the matter of Insulet Corporation vs. EOFlow et al., a jury verdict was returned in favor of Insulet on.
Positive
Zacks Investment Research
6 days ago
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
1 week ago
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Positive
Seeking Alpha
2 weeks ago
Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectations and potential competition from giants like Medtronic and Abbott pose significant risks to Insulet's future performance. The company's financials are robust, with rising revenues, margins, and a strong cash position, but the stock's high valuation demands continued exceptional growth.
Neutral
Business Wire
2 weeks ago
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S. “We are excited to announce that Omnipod 5, the only AID system.
Neutral
Business Wire
2 weeks ago
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m. The Nasdaq 51st Investor Conference in London on Tuesday, December 10, 2024 at 5:30 a.m. The J.P. Morgan 43rd An.
Positive
Zacks Investment Research
3 weeks ago
Buy Profitable S&P 500 Stocks as the Index Tops 6000: NVIDIA & 2 More
NVIDIA, Insulet and Howmet Aerospace have been selected as the top picks with a high net income ratio.
Positive
Zacks Investment Research
3 weeks ago
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
3 weeks ago
PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up
Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5.
Charts implemented using Lightweight Charts™